Seribantumab is a monoclonal IgG2 antibody against ErbB3, and it has also been shown to be a potentially beneficial treatment for NRG1-fusion cancers (Laskin et al., 2020; Nagasaka and Ou, 2022; Schram et al., 2022). This evidence concerns the gene NRG1 and cancer.